Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Humanized Monoclonal Antibody 3F8

Known as: Hu3F8, Humanized Anti-GD2 Antibody 3F8 
A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Importance Chimeric and murine anti-GD2 antibodies are active against neuroblastoma, but the development of neutralizing… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2017
2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.
Fifty-seven stage 4 patients with refractory/relapsed neuroblastoma were enrolled in a phase I trial (Clinicaltrials.gov… Expand
Is this relevant?
2015
2015
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8*
Background: Modest affinity to carbohydrate targets limits the therapeutic efficacy of antibodies to tumor antigens, such as… Expand
  • figure 1
  • figure 2
  • table 2
  • table 1
  • figure 3
Is this relevant?
2014
2014
Large Molecule Therapeutics Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD 2 Using an IgG-scFv Bispeci fi c Antibody with High Af fi nity for GD 2 and DOTA Metal Complex
Bispecific antibodies (BsAb) haveproven to beuseful targeting vectors for pretargeted radioimmunotherapy (PRIT). We sought to… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2012
2012
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Murine IgG3 anti-GD2 antibody m3F8 has shown anti-neuroblastoma activity in Phase I/II studies, where antibody-dependent cell… Expand
  • table 4
  • table 6
  • table 7
  • table 8
  • table 9
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE